IOTA Pharmaceuticals Ltd and the Experimental Therapeutic Unit of the Neurology Department of Massachusetts General Hospital announced the creation of a new Glioblastoma drug screening pipeline, PHOENIX™.
CAMBRIDGE, England and BOSTON, Nov. 20, 2019 /PRNewswire/ -- IOTA Pharmaceuticals Ltd (Cambridge, UK) and the Experimental Therapeutic Unit of the Neurology Department of Massachusetts General Hospital (Neurology, MGH, Boston, USA) today announced the creation of a new Glioblastoma drug screening pipeline, PHOENIX™.
Based on IOTA’s GBM Drug Bank1 and MGH’s Glioblastoma patient-derived cell screening platforms2, PHOENIX™ will translate IOTA’s preclinical work on drug-induced gene expression in established GBM cell lines into a clinic-facing pipeline of effective drug combinations that could form the basis for personalised glioblastoma treatments.
The establishment of PHOENIX™ and the initial findings which have informed the platform will be reported at the American Society for Neuro Oncology meeting being held later this week in Phoenix, Arizona.
PHOENIX™ has been created with funds received from The Brain Tumour Charity (UK).
1 GBM Drug Bank-a new resource for glioblastoma drug discovery and informatics research.
2 Patient-Derived Glioma Models: From Patients to Dish to Animals.
Information on the PHOENIX™ pipeline, and how you can participate, can be obtained from Prof Bakhos Tannous at MGH (btannous@hms.harvard.edu) and Dr David Bailey at IOTA (david.bailey@iotapharma.com).
View original content to download multimedia:http://www.prnewswire.com/news-releases/iota-and-massgen-hospital-establish-phoenix-an-open-access-preclinical-glioblastoma-drug-screening-pipeline-300962215.html
SOURCE IOTA Pharmaceuticals Ltd